Ivonescimab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Ivonescimab
- ak 112
- AK-112
- ak104 ak112
- ak112
- Ak112
- AK112
- AK112 (New Site)
- AK112 (Original Site)
- AK112 Injection
- Drug: Ivonescimab Injection
- Immunoglobulin G1 [240-alanine,241-alanine], anti-(human vascular endothelial growth factor A) (human-Mus musculus monoclonal AK112 γ1-chain) fusion protein with peptide linker (GGGS)4 fusion protein with immunoglobulin anti-(human programmed cell death protein 1) (human-Mus musculus heavy chain V-D-J region) fusion protein with peptide linker (GGGS)4 fusion protein with immunoglobulin anti-(human programmed cell death protein 1) (human-Mus musculus κ-chain V-J region), disulfide with human-Mus musculus monoclonal AK112 κ-chain, dimer
- immunoglobulin g1 240 alanine 241 alanine anti human vascular endothelial growth factor a human mus musculus monoclonal ak112 γ1 chain fusion protein with peptide linker gggs 4 fusion protein with immunoglobulin anti human programmed cell death protein 1 human mus musculus heavy chain v d j region fusion protein with peptide linker gggs 4 fusion protein with immunoglobulin anti human programmed cell death protein 1 human mus musculus κ chain v j region disulfide with human mus musculus monoclonal ak112 κ chain dimer
- immunoglobulin g1 kappa scfv anti homo sapiens vegfa vascular endothelial growth factor a vegf a vegf each heavy chain being fused to a scfv anti homo sapiens pdcd1 programmed cell death 1 pd1 pd 1 cd279 monoclonal antibody tetravalent bispecific gamma1 heavy chain anti vegfa fused to scfv anti pdcd1 1 719 gamma1 heavy chain anti vegfa 1 453 vh homo sapiens ighv3 30 02 76 8 ighd ighj4 01 93 3 cdr imgt 8 8 16 26 33 51 58 97 112 1 123 homo sapiens ighg1 01 g1m17 1 g1v14 ch2 a1 3 a1 2 ch1 k120 220 124 221 hinge 1 15 222 236 ch2 l1 3 a 240 l1 2 a 241 237 346 ch3 d12 362 l14 364 347 451 chs 452 453 124 453 20 mer tetrakis tetraglycyl seryl linker 454 473 scfv vh v kappa anti pdcd1 474 719 vh homo sapiens ighv3 23 04 88 7 ighd ighj6 01 90 9 t123 l 586 cdr imgt 8 8 11 499 506 524 531 570 580 474 591 20 mer tetrakis tetraglycyl seryl linker 592 611 v kappa musmus homsap mus musculus igkv14 111 01 86 3 igkj5 01 100 homo sapiens igkv1 16 01 80 0 igkj2 01 87 5 q120 a 711 cdr imgt 6 3 9 638 643 661 663 700 708 612 719 226 214 disulfide with kappa light chain anti vegfa 1 214 v kappa homo sapiens igkv1 16 01 88 4 igkj1 01 100 cdr imgt 6 3 9 27 32 50 52 89 97 1 107 homo sapiens igkc 01 100 km3 a45 1 153 v101 191 108 214 dimer 232 232 235 235 bisdisulfide produced in chinese hamster ovary cho cells glycoform alfa
- immunoglobulin G1-kappa_scFv, anti-[Homo sapiens VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)], each heavy chain being fused to a scFv anti-[Homo sapiens PDCD1 (programmed cell death 1, PD1, PD-1, CD279)], monoclonal antibody, tetravalent, bispecific; gamma1 heavy chain anti-VEGFA fused to scFv anti-PDCD1 (1-719) [gamma1 heavy chain anti-VEGFA (1-453) [VH (Homo sapiens IGHV3-30*02 (76.8%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.8.16] (26-33.51-58.97-112)) (1-123) -Homo sapiens IGHG1*01, G1m17,1, G1v14 CH2 A1.3, A1.2 (CH1 K120 (220) (124-221), hinge 1-15 (222-236), CH2 L1.3>A (240), L1.2>A (241) (237-346), CH3 D12 (362), L14 (364) (347-451), CHS (452-453)) (124-453)] -20-mer tetrakis(tetraglycyl-seryl) linker (454-473) -scFv-VH-V-KAPPA anti-PDCD1 (474- 719) [VH (Homo sapiens IGHV3-23*04 (88.7%) -(IGHD) -IGHJ6*01 (90.9%) T123>L (586), CDR-IMGT [8.8.11] (499-506.524-531.570-580)) (474-591) -20- mer tetrakis(tetraglycyl-seryl) linker (592-611) -V-KAPPA Musmus/Homsap (Mus musculus IGKV14-111*01 (86.3%) -IGKJ5*01 (100%)/Homo sapiens IGKV1- 16*01 (80.0%) -IGKJ2*01 (87.5%) Q120>A (711), CDR-IMGT [6.3.9] (638- 643.661-663.700-708)) (612-719)], (226-214')-disulfide with kappa light chain anti-VEGFA (1'-214') [V-KAPPA (Homo sapiens IGKV1-16*01 (88.4%) - IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (232-232'':235-235'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
- ivonescimab
- Ivonescimab
- Ivonescimab (SMT112 or AK112) Injection
- ivonescimab [INN]
- IVONESCIMAB [USAN]
- Ivonescimab [WHO-DD]
- Ivonescimab Injection
- ivonescimab inn
- ivonescimab usan
- ivonescimab who dd
- Lvonescimab (AK112)
And 4 more, listed on the interactive page.
- CAS registry numbers
- 2428381-53-5
- ChEMBL ID
- CHEMBL6068451
- FDA ingredient codes (UNII)
- Y0O332CU66
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- ivonescimab
- Type
- Antibody
- Drug name stem
- -mab
- Approval recorded by Guide to Pharmacology
- Yes
Mechanisms of action
- Action
- Binding
- Action type
- Binding
- Target
- programmed cell death 1 (CD279)
- Gene symbol
- PDCD1
- Protein identifier
- Q15116
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Triple Negative Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005537
- Subject identifier
- D064726
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005575
- Subject identifier
- D015179
- Condition identifier
- EFO_0000182
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000702
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000708
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003860
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005922
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000359
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000485
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000576
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001012
- Highest recorded phase
- 1
- Condition identifier
- EFO_1001480
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001927
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000448
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000521
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000544
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001325
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002120
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002367
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002649
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002974
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0003060
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0003219
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0003308
- Highest recorded phase
- 2
And 46 more, listed on the interactive page.
- Event
- anaemia
- Reports
- 5
- Reporting signal score
- 16.9242
- Event
- aspartate aminotransferase increased
- Reports
- 2
- Reporting signal score
- 6.37947
- Event
- biliary tract disorder
- Reports
- 1
- Reporting signal score
- 6.40325
- Event
- decreased appetite
- Reports
- 3
- Reporting signal score
- 8.99762
- Event
- endocrine disorder
- Reports
- 1
- Reporting signal score
- 6.78159
- Event
- fatigue
- Reports
- 5
- Reporting signal score
- 12.3454
- Event
- gastrointestinal disorder
- Reports
- 2
- Reporting signal score
- 6.98039
- Event
- hyperbilirubinaemia
- Reports
- 3
- Reporting signal score
- 16.3299
- Event
- hypertension
- Reports
- 4
- Reporting signal score
- 12.7799
- Event
- hyperthyroidism
- Reports
- 2
- Reporting signal score
- 9.57268
- Event
- hypoalbuminaemia
- Reports
- 4
- Reporting signal score
- 24.8646
- Event
- hypokalaemia
- Reports
- 2
- Reporting signal score
- 6.99414
- Event
- hypothyroidism
- Reports
- 3
- Reporting signal score
- 14.1504
- Event
- immune effector cell-associated neurotoxicity syndrome
- Reports
- 1
- Reporting signal score
- 6.30152
- Event
- leukopenia
- Reports
- 3
- Reporting signal score
- 11.4774
- Event
- myocardial necrosis marker increased
- Reports
- 1
- Reporting signal score
- 6.50483
- Event
- neutropenia
- Reports
- 4
- Reporting signal score
- 13.2694
- Event
- palmar-plantar erythrodysaesthesia syndrome
- Reports
- 3
- Reporting signal score
- 14.0171
- Event
- pneumonitis
- Reports
- 3
- Reporting signal score
- 14.0255
- Event
- post embolisation syndrome
- Reports
- 1
- Reporting signal score
- 8.67634
- Event
- rash
- Reports
- 5
- Reporting signal score
- 14.2373
- Event
- thrombocytopenia
- Reports
- 5
- Reporting signal score
- 18.9049
- Event
- transaminases increased
- Reports
- 2
- Reporting signal score
- 7.89095
- Event
- vomiting
- Reports
- 4
- Reporting signal score
- 9.64434
- NCT04047290
- NCT04597541
- NCT05689853
- NCT04736823
- NCT04900363
- NCT05247684
- NCT05499390
- NCT05636267
- NCT05904379
- NCT05116007
- NCT06478043
- NCT05214482
- NCT05229497
- NCT05227664
- NCT05432492
- NCT05846867
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain
- Type
- Protein
- Sequence
- EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELKR
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 134'-194' $ 134'''-194''' $ 150-206 $ 150''-206'' $ 226-214' $ 226''-214''' $ 232-232'' $ 235-235'' $ 267-327 $ 267''-327'' $ 373-431 $ 373''-431'' $ 495-569 $ 495''-569'' $ 634-699 $ 634''-699''
- Component
- Light chain
- Type
- Protein
- Sequence
- DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Glycosylation sites (N)
- Sequence
- 303 $ 303''
Related records
Trials (165)
- A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation
- A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN)
- A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
- A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
- A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
- A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
- A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
- A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment
- A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
- A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC
- A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
- A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
- A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma
- A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
- A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
- A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
- A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer
- A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
- A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer
- A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
In development for (17)
- Biliary tract cancer Phase 3
- Breast cancer Phase 2
- Cancer Phase 1
- Colorectal cancer Phase 1
- Esophageal squamous cell carcinoma Phase 2
- Female breast carcinoma Phase 2
- Hepatocellular carcinoma Phase 2
- Malignant pancreatic neoplasm Phase 3
- Neoplasm Phase 1
- Non-small cell lung carcinoma Phase 3
- Non-small cell squamous lung carcinoma Phase 3
- Pancreatic neoplasm Phase 3
- Pleural mesothelioma Phase 2
- Small cell lung carcinoma Phase 2
- Squamous cell lung carcinoma Phase 2
- Thymic carcinoma Phase 2
- Triple-negative breast carcinoma Phase 2
Other linked conditions (1)
- Glioblastoma